DexCom (DXCM) Shares Gap Up to $136.59

DexCom, Inc. (NASDAQ:DXCM)’s share price gapped up prior to trading on Tuesday . The stock had previously closed at $139.54, but opened at $136.59. DexCom shares last traded at $124.17, with a volume of 1151404 shares.

A number of brokerages have recently commented on DXCM. BidaskClub raised shares of DexCom from a “buy” rating to a “strong-buy” rating in a report on Tuesday, August 21st. Bank of America increased their price target on shares of DexCom from $127.00 to $145.00 and gave the stock a “buy” rating in a report on Wednesday, August 15th. Stephens increased their price target on shares of DexCom from $135.00 to $160.00 and gave the stock an “overweight” rating in a report on Thursday, August 23rd. Canaccord Genuity increased their price target on shares of DexCom from $125.00 to $150.00 and gave the stock a “buy” rating in a report on Thursday, August 23rd. Finally, Robert W. Baird increased their price target on shares of DexCom from $140.00 to $160.00 and gave the stock a “positive” rating in a report on Thursday, August 23rd. Nine analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $132.65.

The company has a market cap of $11.51 billion, a PE ratio of -220.53 and a beta of 0.55. The company has a current ratio of 4.71, a quick ratio of 4.43 and a debt-to-equity ratio of 0.60.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings results on Tuesday, November 6th. The medical device company reported $0.17 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.12) by $0.29. The business had revenue of $266.70 million during the quarter, compared to analysts’ expectations of $242.72 million. DexCom had a net margin of 4.72% and a negative return on equity of 2.89%. The company’s revenue was up 44.5% compared to the same quarter last year. On average, analysts predict that DexCom, Inc. will post -0.12 earnings per share for the current year.

In other DexCom news, CEO Kevin R. Sayer sold 25,495 shares of the stock in a transaction on Monday, September 10th. The shares were sold at an average price of $143.62, for a total transaction of $3,661,591.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Andrew K. Balo sold 5,000 shares of the stock in a transaction on Friday, September 14th. The shares were sold at an average price of $145.17, for a total transaction of $725,850.00. The disclosure for this sale can be found here. Insiders have sold a total of 149,745 shares of company stock valued at $21,210,998 in the last three months. 1.80% of the stock is currently owned by corporate insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. lifted its position in shares of DexCom by 11.5% in the 3rd quarter. Vanguard Group Inc. now owns 7,942,861 shares of the medical device company’s stock worth $1,136,147,000 after purchasing an additional 816,247 shares during the period. Morgan Stanley lifted its position in shares of DexCom by 16.3% in the 2nd quarter. Morgan Stanley now owns 5,028,874 shares of the medical device company’s stock worth $477,644,000 after purchasing an additional 705,072 shares during the period. BlackRock Inc. lifted its position in shares of DexCom by 5.9% in the 2nd quarter. BlackRock Inc. now owns 4,116,421 shares of the medical device company’s stock worth $390,978,000 after purchasing an additional 228,933 shares during the period. Capital International Investors purchased a new stake in shares of DexCom in the 3rd quarter worth about $475,951,000. Finally, Point72 Asset Management L.P. lifted its position in shares of DexCom by 25.1% in the 2nd quarter. Point72 Asset Management L.P. now owns 1,225,344 shares of the medical device company’s stock worth $116,383,000 after purchasing an additional 246,169 shares during the period. 99.05% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: “DexCom (DXCM) Shares Gap Up to $136.59” was originally published by Community Financial News and is the property of of Community Financial News. If you are viewing this report on another site, it was stolen and republished in violation of U.S. & international copyright & trademark law. The original version of this report can be read at https://www.com-unik.info/2018/12/04/dexcom-dxcm-shares-gap-up-to-136-59.html.

DexCom Company Profile (NASDAQ:DXCM)

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.

Featured Article: What does EPS mean?

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit